SCHEMBL4743441

SCHEMBL4743441

N[C@@H](CS)C(=O)OC(=O)CS

nearest known ligand 0.46

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.46
SLC7A11 Q9UPY5 1/20 0.46
TSHR P16473 1/20 0.37
HSD17B10 Q99714 1/20 0.37
ENPEP Q07075 4/20 0.32
ANPEP P15144 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19511523 0.98 PTGS1 (0.44) PTGS1SLC7A11TSHRHSD17B10ENPEP
SCHEMBL7927272 0.86 PTGS1 (0.46) PTGS1SLC7A11ENPEPANPEP
SCHEMBL9763734 0.86 PTGS1 (0.46) PTGS1SLC7A11TSHRHSD17B10ENPEP
SCHEMBL2873837 0.86 PTGS1 (0.46) PTGS1SLC7A11ENPEPANPEP
SCHEMBL1964879 0.85 PTGS1 (0.55) PTGS1SLC7A11ENPEPANPEP
SCHEMBL20657045 0.85 PTGS1 (0.55) PTGS1SLC7A11ENPEPANPEP
SCHEMBL5688404 0.84 PTGS1 (0.44) PTGS1SLC7A11TSHRHSD17B10ENPEP
SCHEMBL361160 0.84 PTGS1 (0.44) PTGS1SLC7A11ENPEPANPEP
SCHEMBL8601950 0.84 TSHR (0.36) PTGS1SLC7A11TSHRHSD17B10
SCHEMBL5149928 0.84 PTGS1 (0.44) PTGS1SLC7A11ENPEPANPEP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020155081-A1 Use of tris(hydroxymethyl) aminomethane in cold permanent waving processes PROCTER & GAMBLE COMPANY, THE 2002-10-24 US claimed
US-6426065-B1 MIXTURE CONTAINING REDUCING AGENT CLAIROL INCORPORATED 2002-07-30 US claimed
WO-2002038114-A1 USE OF TRIS(HYDROXYMETHYL)AMINOMETHANE IN COLD PERMANENT WAVING PROCESSES P&G-CLAIROL, INC. (US) 2002-05-16 WO claimed
US-5776962-A Lactone compounds for treating patient with precancerous lesions CELL PATHWAYS, INC. (US) 1998-07-07 US claimed
WO-2008092841-A1 METHOD OF DETECTING PREVIOUS STRAIGHTENING BY THE ACTION OF AN ALKALINE AGENT L'OREAL (FR) 2008-08-07 WO disclosed
EP-1033953-B1 METHOD OF CROSS-LINKING KERATIN-BASED FILMS, SHEETS, AND BULK MATERIALS KERAPLAST TECH LTD (US) 2008-03-26 EP disclosed
EP-1033953-A4 METHOD OF CROSS-LINKING KERATIN-BASED FILMS, SHEETS, AND BULK MATERIALS KERAPLAST TECH LTD (US) 2004-12-29 EP disclosed
US-20030035820-A1 Keratin containing implant material SOUTHWEST RESEARCH INSTITUTE AND KERAPLAST TECHNOLOGIES, LTD. 2003-02-20 US disclosed
US-20020155081-A1 Use of tris(hydroxymethyl) aminomethane in cold permanent waving processes PROCTER & GAMBLE COMPANY, THE 2002-10-24 US disclosed
US-6432435-B1 Keratin-based tissue engineering scaffold KERAPLAST TECHNOLOGIES, LTD. 2002-08-13 US disclosed
US-6426065-B1 MIXTURE CONTAINING REDUCING AGENT CLAIROL INCORPORATED 2002-07-30 US disclosed
WO-2002038114-A1 USE OF TRIS(HYDROXYMETHYL)AMINOMETHANE IN COLD PERMANENT WAVING PROCESSES P&G-CLAIROL, INC. (US) 2002-05-16 WO disclosed
US-6159495-A Porous and bulk keratin bio-polymers KERAPLAST TECHNOLOGIES, LTD. (US) 2000-12-12 US disclosed
US-6124265-A Method of making and cross-linking keratin-based films and sheets KERAPLAST TECHNOLOGIES, LTD. (US) 2000-09-26 US disclosed
EP-1033953-A1 METHOD OF CROSS-LINKING KERATIN-BASED FILMS, SHEETS, AND BULK MATERIALS Keraplast Technologies Ltd. (US) 2000-09-13 EP disclosed
US-6110487-A Method of making porous keratin scaffolds and products of same KERAPLAST TECHNOLOGIES LTD. (US) 2000-08-29 US disclosed
WO-1999026570-A1 METHOD OF CROSS-LINKING KERATIN-BASED FILMS, SHEETS, AND BULK MATERIALS KERAPLAST TECHNOLOGIES, LTD. (US) 1999-06-03 WO disclosed
EP-0460921-B1 Large intestinal dissociative hard capsules AICELLO CHEMICAL CO (JP) 1995-03-01 EP disclosed
US-5283064-A The wall is made of chitosans and coated with soluble polymer; AICELLO CHEMICAL CO., LTD. (JP) 1994-02-01 US disclosed
EP-0460921-A2 Large intestinal dissociative hard capsules AICELLO CHEMICAL COMPANY LIMITED (JP) 1991-12-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020155081-A1 Use of tris(hydroxymethyl) aminomethane in cold permanent waving processes MGMT, TET1, TET3 PTGS1 398/4885SLC7A11 2609/4885TSHR 2864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.